ALVO
Alvotech Sa
NASDAQ · Biotechnology
$5.12
+0.13 (+2.61%)
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 548.91M | 146.14M | 133.98M | 123.74M |
| Net Income | -258,687,717 | 28.46M | 26.13M | 29.17M |
| EPS | — | — | — | — |
| Profit Margin | -47.1% | 19.5% | 19.5% | 23.6% |
| Rev Growth | +131.4% | +3.3% | +20.0% | +10.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | — | 380.05M | 315.40M | 394.86M |
| Total Equity | — | 792.19M | 787.29M | 748.59M |
| D/E Ratio | — | 0.48 | 0.40 | 0.53 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 10.34M | 50.85M | 43.53M | 37.02M |
| Free Cash Flow | — | 28.40M | 33.36M | 27.22M |